Search

The four new ligands, dialkyl esters of (S,S)-propylenediamine-N,N′-di-(2,2′-di-(4-hydroxy-benzil))acetic acid (R2-S,S-pddtyr·2HCl) (R = ethyl (L1), propyl (L2), butyl (L3), and pentyl (L4)) and corresponding palladium(II) complexes have been synthesized and characterized by microanalysis, infrared, 1H NMR and 13C NMR spectroscopy. In vitro cytotoxicity was evaluated using the MTT assay on four tumor cell lines, including mouse mammary (4T1) and colon (CT26), and human mammary (MDA-MD-468) and colon (HCT116), as well as non-tumor mouse mesenchymal stem cells. Using fluorescence spectroscopy were investigated the interactions of new palladium(II) complexes [PdCl2(R2-S,S-pddtyr)]; (R = ethyl (C1), propyl (C2), butyl (C3), and pentyl (C4)) with calf thymus human serum albumin (HSA) and DNA (CT-DNA). The high values of the binding constants, Kb, and the Stern–Volmer quenching constant, KSV, show the good binding of all complexes for HSA and CT-DNA. The mentioned ligands and complexes were also tested on in vitro antimicrobial activity against 11 microorganisms. Testing was performed by the microdilution method, where the minimum inhibitory concentration (MMC) and the minimum microbicidal concentration (MMC) were determined. [ABSTRACT FROM AUTHOR]

Introduction. Deep vein thrombosis and pulmonary thromboembolism are among the most important causes of morbidity and mortality in cancer patients. They are common and serious complications that are affected by various risk factors. The aim of this study was to determine the incidence of thromboembolic complications and their association with risk factors in patients with newly diagnosed multiple myeloma. Material and Methods. A retrospective study included 32 patients and the following variables were collected: age, C-reactive protein, beta-2 microglobulin, hemoglobin, platelets, total proteins, nephrotic syndrome, fibrinogen, D-dimer, albumin, lactate dehydrogenase, creatinine, calcium, gender, performance status, type of multiple myeloma, clinical stage, and applied therapy. All variables were compared between two groups of patients: group with thromboembolic complications (deep venous thrombosis and pulmonary thromboembolism), and the group without these complications. Results. The study sample included 18 men and 14 women. The patients’ age ranged from 36 to 73 years. Of the 32 patients, 6 had deep venous thrombosis of the lower extremities, and 2 patients had deep venous thrombosis and pulmonary thromboembolism. The only two biomarkers that showed an association with venous thromboembolism in our patients with myeloma were elevated levels of C-reactive protein and D-dimer. Conclusion. The incidence of thromboembolic complications in patients with newly diagnosed multiple myeloma was 25%. When making the diagnosis of myeloma, risk factors that were significantly associated with venous thromboembolism were elevated levels of C-reactive protein and D-dimer. The occurrence of venous thromboembolism in patients with multiple myeloma was not associated with significantly higher mortality compared to patients without venous thromboembolism. [ABSTRACT FROM AUTHOR]

The four new ligands, dialkyl esters of ( S , S )-propylenediamine- N , N '-di-(2,2'-di-(4-hydroxy-benzil))acetic acid (R 2 - S , S -pddtyr·2HCl) (R = ethyl (L1), propyl (L2), butyl (L3), and pentyl (L4)) and corresponding palladium(II) complexes have been synthesized and characterized by microanalysis, infrared, 1 H NMR and 13 C NMR spectroscopy. In vitro cytotoxicity was evaluated using the MTT assay on four tumor cell lines, including mouse mammary (4T1) and colon (CT26), and human mammary (MDA-MD-468) and colon (HCT116), as well as non-tumor mouse mesenchymal stem cells. Using fluorescence spectroscopy were investigated the interactions of new palladium(II) complexes [PdCl 2 (R 2 - S , S -pddtyr)]; (R = ethyl (C1), propyl (C2), butyl (C3), and pentyl (C4)) with calf thymus human serum albumin (HSA) and DNA (CT-DNA). The high values of the binding constants, K b , and the Stern-Volmer quenching constant, K SV , show the good binding of all complexes for HSA and CT-DNA. The mentioned ligands and complexes were also tested on in vitro antimicrobial activity against 11 microorganisms. Testing was performed by the microdilution method, where the minimum inhibitory concentration (MMC) and the minimum microbicidal concentration (MMC) were determined.